The invention encompasses novel salts of topiramate, and pharmaceutically acceptable polymorphs, solvates, hydrates, dehydrates, co-crystals, anhydrous, or amorphous forms thereof, as well as pharmaceutical compositions and pharmaceutical unit dosage forms containing the same. In particular, the invention encompasses pharmaceutically acceptable salts of topiramate, including without limitation topiramate sodium, topiramate lithium, topiramate potassium, or polymorphs, solvates, hydrates, dehydrates, co-crystals, anhydrous, and amorphous forms thereof. The invention further encompasses novel co-crystals or complexes of topiramate, as well as pharmaceutical compositions comprising them. The invention also encompasses methods of treating or preventing a variety of diseases and conditions including, but not limited to, seizures, epileptic conditions, tremors, cerebral function disorders, obesity, neuropathic pain, affective disorders, tobacco cessation, migraines, and cluster headache.
This application is a continuation of U.S. application Ser. No. 10/232,589 now U.S. Pat. No. 6,559,293, filed Sep. 3, 2002, the entirety of which is incorporated herein by reference, and claims priority to U.S. provisional patent application nos. 60/356,764, filed Feb. 15, 2002, U.S. Ser. No. 60/380,288, filed May 15, 2002, and U.S. Ser. No. 60/406,974, filed Aug. 30, 2002, all of which are incorporated herein by reference in their entireties.
A method for treating macular degeneration and/or treating optic nerve degeneration of a patient comprises administering topiramate with a dosage pharmaceutically effective to suppress degeneration or induce growth of new optic nerve fibers over a sustained period.
